Background: Lack of efficient drug and gene delivery is one of the major problems of cancer chemo- and bio-therapy. This work is focused on optimization of ultrasound-induced delivery of model macromolecular anti-cancer drugs and DNA in human cancer cells.
Materials And Methods: FITC dextrans simulated antisense oligonucleotides (10 kDa), antibodies (70 kDa), and genes (2000 kDa). Optimization of ultrasound frequency, intensity, duty cycle, time of irradiation, and concentration of Optison (ultrasound contrast agent) was performed.
Results: Optimal parameters provided in the MCF7 cell line 73.5+/-3.3%, 72.7+/-0.9%, and 62.7+/-2.1% delivery of 10-kDa, 70-kDa, and 2000-kDa macromolecules, respectively, 36.7+/-4.9% of cell transfection, while dead cell count was only 13.5+/-1.6%. Statistically significant drug delivery and transfection was obtained in all tested cell lines.
Conclusion: These results suggest that optimized treatment parameters provide efficient drug and gene delivery in cancer cells and could be used for further in vivo and in vitro experiments.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial resistance, virulence profiling, and drug repurposing analysis of Staphylococcus aureus from camel mastitis.
Vet Res Commun
December 2024
Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan.
Camel mastitis especially caused by Staphylococcus aureus (S. aureus), is a major risk to animal health and milk production. The current investigation evaluated the antibiotic susceptibility and virulence factors of S.
View Article and Find Full Text PDFDiscovery of a Chimeric Polyketide Family as Cancer Immunogenic Chemotherapeutic Leads.
J Am Chem Soc
December 2024
Department of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina 29208, United States.
Discovery of cancer immunogenic chemotherapeutics represents an emerging, highly promising direction for cancer treatment that uses a chemical drug to achieve the efficacy of both chemotherapy and immunotherapy. Herein, we report a high-throughput screening platform and the subsequent discovery of a new class of cancer immunogenic chemotherapeutic leads. Our platform integrates informatics-based activity metabolomics for the rapid identification of microbial natural products with both novel structures and potent activities.
View Article and Find Full Text PDFAnnual Banned-Substance Review 17th Edition-Analytical Approaches in Human Sports Drug Testing 2023/2024.
Drug Test Anal
December 2024
Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
The 17th edition of the annual banned-substance review on analytical approaches in human sports drug testing is dedicated to literature published between October 2023 and September 2024. As in previous years, focus is put particularly on new or enhanced analytical options in human doping controls as well as investigations into the metabolism and elimination of compounds of interest, which represent central (while not exclusive) cornerstones of the global anti-doping mission. New information published within the past 12 months on established doping agents as well as new potentially relevant substances are reviewed and discussed in the context of the World Anti-Doping Agency's 2024 Prohibited List.
View Article and Find Full Text PDFSuper-enhancer Activates Master Transcription Factor NR3C1 Expression and Promotes 5-FU Resistance in Gastric Cancer.
Adv Sci (Weinh)
December 2024
Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Poor response to 5-fluorouracil (5-FU) remains an obstacle in the treatment of gastric cancer (GC). Super enhancers (SEs) are crucial for determining tumor cell survival under drug pressure. SE landscapes related to 5-FU-resistance are mapped to GC using chromatin immunoprecipitation-sequencing (ChIP-Seq).
View Article and Find Full Text PDFTherapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor.
Neuro Oncol
December 2024
Department of Molecular Biology, College of Natural Science, Pusan National University, Busan, Republic of Korea.
Background: NF2-related schwannomatosis (NF2-SWN) is associated with multiple benign tumors in the nervous system. NF2-SWN, caused by mutations in the NF2 gene, has developed into intracranial and spinal schwannomas. Because of the high surgical risk and frequent recurrence of multiple tumors, targeted therapy is necessary.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!